Gene Expression Signatures and Response to Imatinib Mesylate in Gastrointestinal Stromal Tumor

PURPOSE: Despite initial efficacy of imatinib mesylate (IM) in most gastrointestinal stromal tumor (GIST) patients, many experience primary/secondary drug resistance. Therefore, clinical management of GIST may benefit from further molecular characterization of tumors before and after IM treatment. E...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Rink, Lori, Skorobogatko, Yuliya, Kossenkov, Andrew, Belinsky, Martin G., Pajak, Thomas, Heinrich, Michael C., Blanke, Charles D., von Mehren, Margaret, Ochs, Michael F., Eisenberg, Burton, Godwin, Andrew K.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2009
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2822341/
https://ncbi.nlm.nih.gov/pubmed/19671739
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-09-0193
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak